BLACK DIAMOND THERAPEUTICS, INC. Depreciation
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Depreciation of $28.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for the quarter ending 2026-06-30 was $28.00K, a 67.44% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for the quarter ending 2026-03-31 was $27.00K, a 68.97% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $66.00K, a 22.35% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $86.00K, a 0.00% change year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for fiscal 2025 was $325.00K, a 5.25% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for fiscal 2024 was $343.00K, a 21.51% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for fiscal 2023 was $437.00K, a 13.98% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. depreciation for fiscal 2022 was $508.00K, a 147.80% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K 10-Q · filed 2026-08-05 | $55.00K 10-Q · filed 2026-08-05 | $121.00K derived: sum of 3 quarters · filed 2026-08-05 | $207.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $27.00K 10-Q · filed 2026-05-07 | $93.00K derived: sum of 2 quarters · filed 2026-05-07 | $179.00K derived: sum of 3 quarters · filed 2026-05-07 | $265.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $152.00K derived: sum of 2 quarters · filed 2026-03-16 | $238.00K derived: sum of 3 quarters · filed 2026-08-05 | $325.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $172.00K derived: sum of 2 quarters · filed 2026-08-05 | $259.00K 10-Q · filed 2025-11-06 | $344.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $86.00K 10-Q · filed 2026-08-05 | $173.00K 10-Q · filed 2026-08-05 | $258.00K derived: sum of 3 quarters · filed 2026-08-05 | $344.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $87.00K 10-Q · filed 2026-05-07 | $172.00K derived: sum of 2 quarters · filed 2026-05-07 | $258.00K derived: sum of 3 quarters · filed 2026-05-07 | $344.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $171.00K derived: sum of 2 quarters · filed 2026-03-16 | $257.00K derived: sum of 3 quarters · filed 2026-03-16 | $343.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $172.00K derived: sum of 2 quarters · filed 2025-11-06 | $258.00K 10-Q · filed 2025-11-06 | $344.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $172.00K 10-Q · filed 2025-08-07 | $258.00K derived: sum of 3 quarters · filed 2025-08-07 | $373.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $86.00K 10-Q · filed 2025-05-12 | $172.00K derived: sum of 2 quarters · filed 2025-05-12 | $287.00K derived: sum of 3 quarters · filed 2025-05-12 | $401.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $201.00K derived: sum of 2 quarters · filed 2025-03-06 | $315.00K derived: sum of 3 quarters · filed 2025-03-06 | $437.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $229.00K derived: sum of 2 quarters · filed 2024-11-05 | $351.00K 10-Q · filed 2024-11-05 | $477.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $236.00K 10-Q · filed 2024-08-06 | $362.00K derived: sum of 3 quarters · filed 2024-08-06 | $491.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $122.00K 10-Q · filed 2024-05-09 | $248.00K derived: sum of 2 quarters · filed 2024-05-09 | $377.00K derived: sum of 3 quarters · filed 2024-05-09 | $505.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $255.00K derived: sum of 2 quarters · filed 2024-03-12 | $383.00K derived: sum of 3 quarters · filed 2024-03-12 | $508.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $257.00K derived: sum of 2 quarters · filed 2023-11-06 | $382.00K 10-Q · filed 2023-11-06 | $505.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $253.00K 10-Q · filed 2023-08-11 | $376.00K derived: sum of 3 quarters · filed 2023-08-11 | $419.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $125.00K 10-Q · filed 2023-05-09 | $248.00K derived: sum of 2 quarters · filed 2023-05-09 | $291.00K derived: sum of 3 quarters · filed 2023-05-09 | $311.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $166.00K derived: sum of 2 quarters · filed 2023-03-09 | $186.00K derived: sum of 3 quarters · filed 2023-03-09 | $205.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $63.00K derived: sum of 2 quarters · filed 2022-11-08 | $82.00K 10-Q · filed 2022-11-08 | $97.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $39.00K 10-Q · filed 2022-08-09 | $54.00K derived: sum of 3 quarters · filed 2022-08-09 | $68.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $19.00K 10-Q · filed 2022-05-11 | $34.00K derived: sum of 2 quarters · filed 2022-05-11 | $48.00K derived: sum of 3 quarters · filed 2022-05-11 | $61.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $29.00K derived: sum of 2 quarters · filed 2022-03-17 | $42.00K derived: sum of 3 quarters · filed 2022-03-17 | $52.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $27.00K derived: sum of 2 quarters · filed 2021-11-08 | $37.00K 10-Q · filed 2021-11-08 | $46.00K derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $23.00K 10-Q · filed 2021-08-12 | $32.00K derived: sum of 3 quarters · filed 2021-08-12 | $45.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $10.00K 10-Q · filed 2021-05-07 | $19.00K derived: sum of 2 quarters · filed 2021-05-07 | $32.00K derived: sum of 3 quarters · filed 2021-05-07 | $45.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $22.00K derived: sum of 2 quarters · filed 2021-03-25 | $35.00K derived: sum of 3 quarters · filed 2021-03-25 | $47.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $26.00K derived: sum of 2 quarters · filed 2020-11-10 | $38.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $25.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $12.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $44.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |